- Home
- MRM vs CARM Comparison
MRM vs CARM Comparison
Compare MRM & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- CARM
- Stock Information
- Founded
- MRM 2000
- CARM 2016
- Country
- MRM Japan
- CARM United States
- Employees
- MRM N/A
- CARM N/A
- Industry
- MRM Other Consumer Services
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- MRM Consumer Discretionary
- CARM Health Care
- Exchange
- MRM Nasdaq
- CARM Nasdaq
- Market Cap
- MRM 10.4M
- CARM 12.2M
- IPO Year
- MRM 2020
- CARM N/A
- Fundamental
- Price
- MRM $1.64
- CARM $0.40
- Analyst Decision
- MRM
- CARM Hold
- Analyst Count
- MRM 0
- CARM 5
- Target Price
- MRM N/A
- CARM $0.90
- AVG Volume (30 Days)
- MRM 7.6M
- CARM 25.2M
- Earning Date
- MRM 05-20-2025
- CARM 11-06-2025
- Dividend Yield
- MRM N/A
- CARM N/A
- EPS Growth
- MRM 27.65
- CARM N/A
- EPS
- MRM 0.18
- CARM N/A
- Revenue
- MRM $52,786,758.00
- CARM $10,767,000.00
- Revenue This Year
- MRM N/A
- CARM N/A
- Revenue Next Year
- MRM N/A
- CARM N/A
- P/E Ratio
- MRM $9.04
- CARM N/A
- Revenue Growth
- MRM 21.55
- CARM N/A
- 52 Week Low
- MRM $0.34
- CARM $0.14
- 52 Week High
- MRM $5.30
- CARM $1.27
- Technical
- Relative Strength Index (RSI)
- MRM 47.41
- CARM 60.37
- Support Level
- MRM $1.42
- CARM $0.21
- Resistance Level
- MRM $1.97
- CARM $0.56
- Average True Range (ATR)
- MRM 0.20
- CARM 0.05
- MACD
- MRM -0.06
- CARM 0.02
- Stochastic Oscillator
- MRM 27.85
- CARM 55.46
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.